A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Inclusion Criteria

• •Histologically proven diagnosis of colorectal adenocarcinoma
• •Part1: Subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
• •Part2: Subjects who have previously received systemic therapy including fluorouracil, oxaliplatin, irinotecan, bevacizumab or anti-EGFR antibodies or could not tolerate or have contraindications to standard treatment
• •Eastern Cooperative Oncology Group performance status of 0 or 1
• •Measurable disease as defined by RECIST v1.1
• •Adequate hematologic and organ function